least common multiple of T and R [Design Issues]

posted by Vishal S – India, 2021-05-25 13:26 (62 d 12:21 ago) – Posting: # 22365
Views: 543

Hii Helmut

Thank you for replay
we are designing the fixed dose combination Immediate release test formulation(A+B) having strength 100 mg (A) and 325 mg (B), RLD for FDC formulation not approved in EU market & not available so we are using two different RLDs ie RLD (A) of 100 mg strength and RLD (B) having 500 mg strength. Note than RLD (B) available in EU market in 500 mg strength, 325 mg strength not available as RLD.
please guide me for BE study for same

Thanks and Regards
Vishal S


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5! [Ohlbe]

Complete thread:

Activity
 Admin contact
21,589 posts in 4,512 threads, 1,530 registered users;
online 3 (0 registered, 3 guests [including 3 identified bots]).
Forum time: Tuesday 01:47 CEST (Europe/Vienna)

The great tragedy of Science – the slaying
of a beautiful hypothesis by an ugly fact.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5